The government may look at areas around Thonnakkal, in Thiruvananthapuram district, for the facility. If successful, this would be one of the few sites of Sputnik V owned by Russian firms......
'Its efficacy is 97.6 per cent.' Morepen India Chairman and Managing Director Sushil Suri in an interview with Uddalok Bhattacharya says the Sputnik V vaccine it is manufacturing in India......
Officers sitting over untapped potential to make COVID-19 vaccines need to be charged with 'manslaughter' as it is leading to so many deaths, the Delhi high court said on Wednesday, observing that......
Domestic pharma major Panacea Biotec in collaboration with Russian sovereign wealth fund Russian Direct Investment Fund (RDIF) has begun the production of 'Sputnik V' COVID-19 vaccine in......
COVID-19 has not spared even a single family and still central government's officers are living in "ivory towers" oblivious of ground realities, observed the Delhi high court which on Tuesday was......
Markets ended lower on Friday, amid weakness in European shares, dragged by oil shares because of declining global crude oil prices. Adding to this, investors were cautious ahead of CPI and IIP......
Markets ended lower on Monday, ahead of the Reserve Bank of India's mid-quarter monetary policy review, weighed down by selling pressure in HDFC Group shares along with ITC and TCS.The 30-share......
Markets ended flat on Monday after moving in a narrow range for most part of the trading session.The Sensex closed higher by 30 points at 18,339 and the 50-share Nifty slipped 3 points to close at......
Key share indices ended marginally lower on Thursday, amid weak global cues, following the expiry of March derivative contracts weighed down by software shares and Larsen & Toubro. The Sensex ended......
Mumbai outpaced Bangalore, with a margin of about Rs 200 crore (Rs 2 billion), to become India's top biotech city in terms of revenue while Bangalore-based bio pharmaceuticals major Biocon clocked......